Mizuho analyst Anthony Petrone lowered the firm’s price target on Nevro to $30 from $40 and keeps a Neutral rating on the shares. The analyst updated medtech and diagnostics price targets ahead of the Q2 reporting season.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVRO: